España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Supernus Pharmaceuticals
SUPN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$36.22
0.4
1.12%
At close: -
$36.22
0
0.00%
After Hours: 4:48 PM EDT
Get Report
Comment
Supernus Pharmaceuticals (SUPN) Forecast
News
Earnings
Supernus Pharmaceuticals (SUPN) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Supernus Pharmaceuticals (NASDAQ:SUPN) Stock
Supernus Pharmaceuticals Stock (NASDAQ: SUPN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, November 04, 2024
Supernus Pharmaceuticals Sees FY24 Total Reve...
Benzinga Newsdesk
Supernus Pharmaceuticals Q3 2024 GAAP EPS $0....
Benzinga Newsdesk
Thursday, October 31, 2024
Supernus Pharmaceuticals From A Phase 2 Study...
Benzinga Newsdesk
Thursday, October 17, 2024
Supernus Reports Data From Open-Label Phase 2...
Benzinga Newsdesk
Wednesday, September 11, 2024
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Vandana Singh
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Avi Kapoor
Supernus Pharmaceuticals shares are trading l...
Benzinga Newsdesk
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
Piper Sandler Downgrades Supernus Pharmaceuti...
Benzinga Newsdesk
Monday, August 19, 2024
FDA Accepts Supernus Pharmaceuticals' Resubmi...
Benzinga Newsdesk
Wednesday, August 07, 2024
Supernus Pharmaceuticals shares are trading h...
Benzinga Newsdesk
Tuesday, August 06, 2024
Supernus Raises 2024 Total Revenue Guidance F...
Benzinga Newsdesk
Supernus Pharmaceuticals Q2 2024 GAAP EPS $0....
Benzinga Newsdesk
Thursday, August 01, 2024
Supernus Resubmits NDA To FDA For SPN-830 Apo...
Benzinga Newsdesk
Thursday, May 23, 2024
Supernus Pharmaceuticals Announces Interim An...
Benzinga Newsdesk
Wednesday, May 08, 2024
Supernus Pharmaceuticals Reiterates FY24 Reve...
Benzinga Newsdesk
Supernus Pharmaceuticals Q1 Sales $143.600M M...
Benzinga Newsdesk
Tuesday, May 07, 2024
M8 Pharmaceuticals Signs An Exclusive Licensi...
Benzinga Newsdesk
Monday, April 08, 2024
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
Vandana Singh
Supernus Pharmaceuticals shares are trading l...
Benzinga Newsdesk
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Supernus Provides Regulatory Update For SPN-8...
Benzinga Newsdesk
Wednesday, February 28, 2024
Piper Sandler Maintains Overweight on Supernu...
Benzinga Newsdesk
Tuesday, February 27, 2024
Supernus Sees FY24 Total Revenue $580M-$620M ...
Benzinga Newsdesk
Recap: Supernus Pharmaceuticals Q4 Earnings
Benzinga Insights
Supernus Pharmaceuticals Q4 2023 Adj EPS $0.3...
Benzinga Newsdesk
Earnings Scheduled For February 27, 2024
Benzinga Insights
Monday, February 05, 2024
Supernus Pharmaceuticals Wins Infringement An...
Benzinga Newsdesk
Tuesday, December 19, 2023
Supernus Pharmaceuticals Has Granted Rights T...
Benzinga Newsdesk
Tuesday, December 12, 2023
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
Vandana Singh
Tuesday, November 21, 2023
Board Member at Supernus Pharmaceuticals Exercises Options Worth $203K
Benzinga Insights
Friday, November 17, 2023
SVP at Supernus Pharmaceuticals Exercises Options Worth $55K
Benzinga Insights
Thursday, November 09, 2023
Piper Sandler Maintains Overweight on Supernu...
Benzinga Newsdesk
Supernus Pharmaceuticals shares are trading h...
Benzinga Newsdesk
Wednesday, November 08, 2023
Supernus Pharmaceuticals Narrows FY23 Revenue...
Benzinga Newsdesk
Supernus Pharmaceuticals: Q3 Earnings Insights
Benzinga Insights
Supernus Pharmaceuticals Q3 2023 EPS $(0.29) ...
Benzinga Newsdesk
Earnings Scheduled For November 8, 2023
Benzinga Insights
Thursday, November 02, 2023
Supernus Pharmaceuticals Disclosed That The U...
Benzinga Newsdesk
Wednesday, October 25, 2023
Piper Sandler Maintains Overweight on Supernu...
Benzinga Newsdesk
Monday, October 09, 2023
Supernus Pharmaceuticals Resubmits NDA For SP...
Benzinga Newsdesk
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
Thursday, September 21, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
Tuesday, September 19, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Friday, September 15, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Sunday, September 10, 2023
Supernus Late Saturday, Announced New Qelbree Data Showing Improvement In ADHD Symptoms
Charles Gross
Tuesday, August 22, 2023
Board Member at Supernus Pharmaceuticals Acquires Company Stock Options Worth 24,153 Shares
Benzinga Insights
Tuesday, August 08, 2023
Supernus Pharmaceuticals Q2 EPS $(0.02) Beats...
Benzinga Newsdesk
Earnings Scheduled For August 8, 2023
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch